{
    "clinical_study": {
        "@rank": "161311", 
        "arm_group": {
            "arm_group_label": "Etanercept", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The hypothesis is that a subset of patients with chronic fatigue syndrome/ myalgic\n      encephalomyelitis (CFS/ME), including also patients with no clinical response after B-cell\n      depletion therapy using the anti-CD20 antibody Rituximab, may benefit from tumor necrosis\n      factor-alpha inhibition using Etanercept as weekly subcutaneous injections."
        }, 
        "brief_title": "Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Fatigue Syndrome", 
            "Myalgic Encephalomyelitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Encephalomyelitis", 
                "Fatigue", 
                "Fatigue Syndrome, Chronic", 
                "Necrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  chronic fatigue syndrome/ myalgic encephalomyelitis (CFS/ME)\n\n          -  moderate and serious CFS/ME severity\n\n          -  age 18-66 years\n\n          -  informed consent\n\n        Exclusion Criteria:\n\n          -  patients with fatigue, not fulfilling criteria for CFS\n\n          -  pregnancy or lactation\n\n          -  previous malignant disease, except basal cell carcinoma of skin and cervical\n             carcinoma in situ\n\n          -  previous long-term systemic treatment with immunosuppressive drugs such as\n             cyclosporine, azathioprin, mycophenolatemofetil, except steroids e.g. in obstructive\n             lunge disease.\n\n          -  demyelinating disease, such as multiple sclerosis.\n\n          -  heart failure.\n\n          -  endogenous depression.\n\n          -  lack of ability to comply to the protocol.\n\n          -  multi-allergy with risk of serious drug reaction\n\n          -  reduced renal function (creatinine > 1.5 x UNL)\n\n          -  reduced liver function (bilirubin or transaminases > 1.5 x UNL)\n\n          -  HIV positivity. Evidence of clinically significant infection. Previous viral\n             hepatitis with risk of reactivation. High risk of opportunistic infections. Latent\n             tuberculosis must be treated before inclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "66 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730495", 
            "org_study_id": "2011/2500", 
            "secondary_id": "2011-006069-16"
        }, 
        "intervention": {
            "arm_group_label": "Etanercept", 
            "description": "Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.", 
            "intervention_name": "Etanercept", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "TNFR-Fc fusion protein"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic fatigue syndrome", 
            "CFS", 
            "Myalgic Encephalomyelitis (ME)", 
            "CFS/ME", 
            "Tumor necrosis factor-alpha", 
            "TNF-alpha", 
            "Etanercept"
        ], 
        "lastchanged_date": "August 28, 2013", 
        "location": {
            "contact": {
                "email": "olav.mella@helse-bergen.no", 
                "last_name": "Olav Mella, MD, PhD", 
                "phone": "47 55972069"
            }, 
            "contact_backup": {
                "email": "oystein.fluge@helse-bergen.no", 
                "last_name": "\u00d8ystein Fluge, MD, PhD", 
                "phone": "47 55972010"
            }, 
            "facility": {
                "address": {
                    "city": "Bergen", 
                    "country": "Norway", 
                    "zip": "N-5021"
                }, 
                "name": "Dept. of Oncology and Medical Physics, Haukeland University Hospital Bergen, Norway"
            }, 
            "investigator": [
                {
                    "last_name": "\u00d8ystein Fluge, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Olav Mella, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "1", 
        "official_title": "Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Moderate and Serious Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), Including in Patients With no Clinical Response After B-lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab.", 
        "overall_contact": {
            "email": "olav.mella@helse-bergen.no", 
            "last_name": "Olav Mella, MD, PhD", 
            "phone": "47 55972069"
        }, 
        "overall_contact_backup": {
            "email": "oystein.fluge@helse-bergen.no", 
            "last_name": "\u00d8ystein Fluge, MD, PhD", 
            "phone": "47 55972010"
        }, 
        "overall_official": {
            "affiliation": "Dept. of Oncology and Medical Physics, Haukeland University Hospital", 
            "last_name": "\u00d8ystein Fluge, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Norway: Directorate of Health", 
                "Norway: Norwegian Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is defined as moderate or major response of the CFS/ME symptoms, of at least six weeks duration, independent on when during 12 months follow-up the response period(s) occurs. Single such response periods, and the sum of these, are recorded.", 
            "measure": "Symptom alleviation within 12 months follow-up, as compared to baseline, measured by standardized self-reports and quality of life schemes.", 
            "safety_issue": "Yes", 
            "time_frame": "Response of at least six weeks duration, independent on when occuring, during 12 months follow-up."
        }, 
        "reference": [
            {
                "PMID": "22039471", 
                "citation": "Fluge \u00d8, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, N\u00e6ss H, Dahl O, Nyland H, Mella O. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358. Epub 2011 Oct 19."
            }, 
            {
                "PMID": "19566965", 
                "citation": "Fluge \u00d8, Mella O. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurol. 2009 Jul 1;9:28."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730495"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary outcome measures are effect on the CFS/ME symptoms, by evaluation at 3, 6, 9, 12 months after start of intervention.", 
            "measure": "Symptom alleviation, as compared to baseline, measured by standardized self-reports and quality of life schemes.", 
            "safety_issue": "Yes", 
            "time_frame": "At 3, 6, 9, 12 months after start of intervention."
        }, 
        "source": "Haukeland University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Haukeland University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}